Short- and long-term survival in treated elderly hypertensive patients with or without diabetes: findings from the Second Australian National Blood Pressure study.

BACKGROUND We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival. METHODS The Second Australian National Blood Pressure (ANBP2) study randomized 6,083 hypertensive patients aged 65-84 years to angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic-based therapy and followed them for a median of 4.1 years. Long-term survival was determined in 5,678 patients over an additional median of 6.9 years after ANBP2 (post-trial). RESULTS After ANBP2, the cohort was classified into preexisting (7.2%), newly diagnosed (5.6%), and no diabetes (87.2%) groups. A 44% higher incidence of newly diagnosed diabetes was observed in patients randomized to thiazide diuretic compared with ACEI-based treatment. The other predictors of newly diagnosed diabetes were having a higher body mass index, having a higher random blood glucose, and living in a regional location compared to major cities (a geographical classification based on accessibility) at study entry. After completion of ANBP2, compared with those with no diabetes, the preexisting diabetes group experienced higher cardiovascular (hazards ratio (HR) = 1.65; 95% confidence interval (CI) = 1.03-2.65) and all-cause mortality (HR = 1.40; 95% CI = 1.02-1.92) when adjusted for age, sex, and treatment. A similar pattern was observed after including the post-trial period for cardiovascular (HR = 1.52; 95% CI = 1.20-1.93) and all-cause mortality (HR = 1.50; 95% CI = 1.29-1.73). However, when the newly diagnosed group was compared with the no diabetes group, no significant difference was observed in cardiovascular (HR = 0.33; 95% CI = 0.11-1.05) or all-cause mortality (HR = 0.76; 95% CI = 0.47-1.23) either during the ANBP2 trial or including post-trial follow-up (cardiovascular: HR = 0.82; 95% CI = 0.58-1.17; all-cause mortality: HR = 1.04; 95% CI = 0.85-1.27). CONCLUSIONS Long-term presence of diabetes reduces survival. Compared with thiazide diuretics, ACEI-based antihypertensives may delay the development of diabetes in those at risk and thus potentially improve cardiovascular outcome in the elderly.

[1]  F. Messerli,et al.  Management of blood pressure in patients with diabetes. , 2011, American journal of hypertension.

[2]  Frank B. Hu,et al.  Globalization of Diabetes , 2011, Diabetes Care.

[3]  G. Mancia,et al.  Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population , 2008, Journal of hypertension.

[4]  S. Kjeldsen,et al.  Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial , 2008, Journal of Human Hypertension.

[5]  J. Shaw,et al.  Glucose Indices, Health Behaviors, and Incidence of Diabetes in Australia , 2007, Diabetes Care.

[6]  J. Nunnelee.  Antihypertensive medications and the risk of incident type 2 diabetes. , 2006, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[7]  B. Davis,et al.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.

[8]  T. Lumley,et al.  New-Onset Diabetes and Risk of All-Cause and Cardiovascular Mortality , 2006, Diabetes Care.

[9]  M. Moser.  Is New‐Onset Diabetes of Clinical Significance in Treated Hypertensive Patients?—Con , 2006, Journal of clinical hypertension.

[10]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[11]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[12]  G. Reboldi,et al.  Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects , 2004, Hypertension.

[13]  L. Eberly,et al.  Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. , 2003, Diabetes care.

[14]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[15]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[16]  B. Yawn,et al.  Impact of case ascertainment on recent trends in diabetes incidence in Rochester, Minnesota. , 2002, American journal of epidemiology.

[17]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[18]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease: An Update , 2001, Hypertension.

[19]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[20]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[21]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[22]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[23]  M. Alderman,et al.  Diabetes and cardiovascular events in hypertensive patients. , 1999, Hypertension.

[24]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[25]  K. Flegal,et al.  Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994 , 1998, Diabetes Care.

[26]  C. Reid,et al.  Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. , 1997, Clinical and experimental pharmacology & physiology.

[27]  Lippincott Williams Wilkins,et al.  National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes , 1994, Hypertension.

[28]  Richard Barnett.  Diabetes , 1904, The Lancet.

[29]  W. Elliott.  Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up , 2008 .

[30]  W. Elliott.  Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial Population , 2008 .

[31]  G. Mancia,et al.  New-onset diabetes and antihypertensive drugs. , 2006, Journal of hypertension.

[32]  Alan C. Wilson,et al.  Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. , 2005, The American journal of cardiology.

[33]  The Origin trial investigators.  Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial , 2004 .

[34]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease , 2001 .

[35]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[36]  B. Psaty,et al.  New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. , 1998, Journal of cardiovascular pharmacology.